Search

Your search keyword '"Lieu, Christopher H."' showing total 10 results
Start Over Author "Lieu, Christopher H." Database OAIster
10 results on '"Lieu, Christopher H."'

1. Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer

Author

Demb, Joshua, Demb, Joshua, Kolb, Jennifer M, Dounel, Jonathan, Fritz, Cassandra DL, Advani, Shailesh M, Cao, Yin, Coppernoll-Blach, Penny, Dwyer, Andrea J, Perea, Jose, Heskett, Karen M, Holowatyj, Andreana N, Lieu, Christopher H, Singh, Siddharth, Spaander, Manon CW, Vuik, Fanny ER, Gupta, Samir, Demb, Joshua, Demb, Joshua, Kolb, Jennifer M, Dounel, Jonathan, Fritz, Cassandra DL, Advani, Shailesh M, Cao, Yin, Coppernoll-Blach, Penny, Dwyer, Andrea J, Perea, Jose, Heskett, Karen M, Holowatyj, Andreana N, Lieu, Christopher H, Singh, Siddharth, Spaander, Manon CW, Vuik, Fanny ER, and Gupta, Samir

Abstract

ImportanceEarly-onset colorectal cancer (EOCRC), defined as a diagnosis at younger than age 50 years, is increasing, and so-called red flag signs and symptoms among these individuals are often missed, leading to diagnostic delays. Improved recognition of presenting signs and symptoms associated with EOCRC could facilitate more timely diagnosis and impact clinical outcomes.ObjectiveTo report the frequency of presenting red flag signs and symptoms among individuals with EOCRC, to examine their association with EOCRC risk, and to measure variation in time to diagnosis from sign or symptom presentation.Data sourcesPubMed/MEDLINE, Embase, CINAHL, and Web of Science were searched from database inception through May 2023.Study selectionStudies that reported on sign and symptom presentation or time from sign and symptom presentation to diagnosis for patients younger than age 50 years diagnosed with nonhereditary CRC were included.Data extraction and synthesisData extraction and quality assessment were performed independently in duplicate for all included studies using Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines. Joanna Briggs Institute Critical Appraisal tools were used to measure risk of bias. Data on frequency of signs and symptoms were pooled using a random-effects model.Main outcomes and measuresOutcomes of interest were pooled proportions of signs and symptoms in patients with EOCRC, estimates for association of signs and symptoms with EOCRC risk, and time from sign or symptom presentation to EOCRC diagnosis.ResultsOf the 12 859 unique articles initially retrieved, 81 studies with 24 908 126 patients younger than 50 years were included. The most common presenting signs and symptoms, reported by 78 included studies, were hematochezia (pooled prevalence, 45% [95% CI, 40%-50%]), abdominal pain (pooled prevalence, 40% [95% CI, 35%-45%]), and altered bowel habits (pooled prevalence, 27% [95% CI, 22%-33%]). Hematochezia (estimate r

Published
2024

2. Red Flag Signs and Symptoms for Patients With Early-Onset Colorectal Cancer:A Systematic Review and Meta-Analysis

Author

Demb, Joshua, Kolb, Jennifer M., Dounel, Jonathan, Fritz, Cassandra D.L., Advani, Shailesh M., Cao, Yin, Coppernoll-Blach, Penny, Dwyer, Andrea J., Perea, Jose, Heskett, Karen M., Holowatyj, Andreana N., Lieu, Christopher H., Singh, Siddharth, Spaander, Manon C.W., Vuik, Fanny E.R., Gupta, Samir, Demb, Joshua, Kolb, Jennifer M., Dounel, Jonathan, Fritz, Cassandra D.L., Advani, Shailesh M., Cao, Yin, Coppernoll-Blach, Penny, Dwyer, Andrea J., Perea, Jose, Heskett, Karen M., Holowatyj, Andreana N., Lieu, Christopher H., Singh, Siddharth, Spaander, Manon C.W., Vuik, Fanny E.R., and Gupta, Samir

Abstract

Importance: Early-onset colorectal cancer (EOCRC), defined as a diagnosis at younger than age 50 years, is increasing, and so-called red flag signs and symptoms among these individuals are often missed, leading to diagnostic delays. Improved recognition of presenting signs and symptoms associated with EOCRC could facilitate more timely diagnosis and impact clinical outcomes. Objective: To report the frequency of presenting red flag signs and symptoms among individuals with EOCRC, to examine their association with EOCRC risk, and to measure variation in time to diagnosis from sign or symptom presentation. Data Sources: PubMed/MEDLINE, Embase, CINAHL, and Web of Science were searched from database inception through May 2023. Study Selection: Studies that reported on sign and symptom presentation or time from sign and symptom presentation to diagnosis for patients younger than age 50 years diagnosed with nonhereditary CRC were included. Data Extraction and Synthesis: Data extraction and quality assessment were performed independently in duplicate for all included studies using Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines. Joanna Briggs Institute Critical Appraisal tools were used to measure risk of bias. Data on frequency of signs and symptoms were pooled using a random-effects model. Main Outcomes and Measures: Outcomes of interest were pooled proportions of signs and symptoms in patients with EOCRC, estimates for association of signs and symptoms with EOCRC risk, and time from sign or symptom presentation to EOCRC diagnosis. Results: Of the 12859 unique articles initially retrieved, 81 studies with 24908126 patients younger than 50 years were included. The most common presenting signs and symptoms, reported by 78 included studies, were hematochezia (pooled prevalence, 45% [95% CI, 40%-50%]), abdominal pain (pooled prevalence, 40% [95% CI, 35%-45%]), and altered bowel habits (pooled prevalence, 27% [95% CI, 22%-33%]). Hema

Published
2024

3. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.

Author

Dasari, Arvind, Dasari, Arvind, Morris, Van K, Allegra, Carmen J, Atreya, Chloe, Benson, Al B, Boland, Patrick, Chung, Ki, Copur, Mehmet S, Corcoran, Ryan B, Deming, Dustin A, Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J, Gollub, Marc J, Goodwin, Rachel A, Hamilton, Stanley R, Hechtman, Jaclyn F, Hochster, Howard, Hong, Theodore S, Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A, Kennecke, Hagen F, Lee, James J, Lieu, Christopher H, Lenz, Heinz-Josef, Lindwasser, O Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J, Shi, Qian, Strickler, John H, Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y Nancy, Zell, Jason A, Kopetz, Scott, Dasari, Arvind, Dasari, Arvind, Morris, Van K, Allegra, Carmen J, Atreya, Chloe, Benson, Al B, Boland, Patrick, Chung, Ki, Copur, Mehmet S, Corcoran, Ryan B, Deming, Dustin A, Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J, Gollub, Marc J, Goodwin, Rachel A, Hamilton, Stanley R, Hechtman, Jaclyn F, Hochster, Howard, Hong, Theodore S, Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A, Kennecke, Hagen F, Lee, James J, Lieu, Christopher H, Lenz, Heinz-Josef, Lindwasser, O Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J, Shi, Qian, Strickler, John H, Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y Nancy, Zell, Jason A, and Kopetz, Scott

Abstract

An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.

Published
2020

4. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.

Author

Dasari, Arvind, Dasari, Arvind, Morris, Van K, Allegra, Carmen J, Atreya, Chloe, Benson, Al B, Boland, Patrick, Chung, Ki, Copur, Mehmet S, Corcoran, Ryan B, Deming, Dustin A, Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J, Gollub, Marc J, Goodwin, Rachel A, Hamilton, Stanley R, Hechtman, Jaclyn F, Hochster, Howard, Hong, Theodore S, Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A, Kennecke, Hagen F, Lee, James J, Lieu, Christopher H, Lenz, Heinz-Josef, Lindwasser, O Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J, Shi, Qian, Strickler, John H, Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y Nancy, Zell, Jason A, Kopetz, Scott, Dasari, Arvind, Dasari, Arvind, Morris, Van K, Allegra, Carmen J, Atreya, Chloe, Benson, Al B, Boland, Patrick, Chung, Ki, Copur, Mehmet S, Corcoran, Ryan B, Deming, Dustin A, Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J, Gollub, Marc J, Goodwin, Rachel A, Hamilton, Stanley R, Hechtman, Jaclyn F, Hochster, Howard, Hong, Theodore S, Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A, Kennecke, Hagen F, Lee, James J, Lieu, Christopher H, Lenz, Heinz-Josef, Lindwasser, O Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J, Shi, Qian, Strickler, John H, Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y Nancy, Zell, Jason A, and Kopetz, Scott

Abstract

An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisciplinary experts to summarize current data on the utility of ctDNA in the management of colorectal cancer and to provide guidance in promoting the efficient development and integration of this technology into clinical care. The panel focused on four key areas in which ctDNA has the potential to change clinical practice, including the detection of minimal residual disease, the management of patients with rectal cancer, monitoring responses to therapy, and tracking clonal dynamics in response to targeted therapies and other systemic treatments. The panel also provides general guidelines with relevance for ctDNA-related research efforts, irrespective of indication.

Published
2020

5. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer : Supported by the ARCAD Group

Author

Goey, Kaitlyn K. H., Sorbye, Halfdan, Glimelius, Bengt, Adams, Richard A., Andre, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Diaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heineman, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans-Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G. H., Punt, Cornelis J. A., Koopman, Miriam, Goey, Kaitlyn K. H., Sorbye, Halfdan, Glimelius, Bengt, Adams, Richard A., Andre, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Diaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heineman, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans-Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G. H., Punt, Cornelis J. A., and Koopman, Miriam

Abstract

Background: Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is substantial heterogeneity in reporting of patient characteristics and use of stratification factors in phase 3 trials investigating systemic treatment of metastatic colorectal cancer (mCRC). We aimed to develop a minimum set of essential baseline characteristics and stratification factors to include in such trials. Methods: We performed a modified, two-round Delphi survey among international experts with wide experience in the conduct and methodology of phase 3 trials of systemic treatment of mCRC. Results: Thirty mCRC experts from 15 different countries completed both consensus rounds. A total of 14 patient characteristics were included in the recommended set: age, performance status, primary tumour location, primary tumour resection, prior chemotherapy, number of metastatic sites, liver-only disease, liver involvement, surgical resection of metastases, synchronous versus metachronous metastases, (K)RAS and BRAF mutation status, microsatellite instability/mismatch repair status and number of prior treatment lines. A total of five patient characteristics were considered the most relevant stratification factors: RAS/BRAF mutation status, performance status, primary tumour sidedness and liver-only disease. Conclusions: This survey provides a minimum set of essential baseline patient characteristics and stratification factors to include in phase 3 trials of systemic treatment of mCRC. Inclusion of these patient characteristics and strata in study protocols and final study reports will improve interpretation of trial results and facilitate cross-study comparisons.

Published
2018
Full Text
View/download PDF

6. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer : Supported by the ARCAD Group

Author

Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., Koopman, Miriam, Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., and Koopman, Miriam

Published
2018

7. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer : Supported by the ARCAD Group

Author

Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., Koopman, Miriam, Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., and Koopman, Miriam

Published
2018

8. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer : Supported by the ARCAD Group

Author

Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., Koopman, Miriam, Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., and Koopman, Miriam

Published
2018

9. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Author

Team 1 Hemat, Onderzoek Medische Oncologie, Cancer, Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., Koopman, Miriam, Team 1 Hemat, Onderzoek Medische Oncologie, Cancer, Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., and Koopman, Miriam

Published
2018

10. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Author

Dotan, Efrat, Dotan, Efrat, Cohen, Steven J, Starodub, Alexander N, Lieu, Christopher H, Messersmith, Wells A, Simpson, Pamela S, Guarino, Michael J, Marshall, John L, Goldberg, Richard M, Hecht, J Randolph, Wegener, William A, Sharkey, Robert M, Govindan, Serengulam V, Goldenberg, David M, Berlin, Jordan D, Dotan, Efrat, Dotan, Efrat, Cohen, Steven J, Starodub, Alexander N, Lieu, Christopher H, Messersmith, Wells A, Simpson, Pamela S, Guarino, Michael J, Marshall, John L, Goldberg, Richard M, Hecht, J Randolph, Wegener, William A, Sharkey, Robert M, Govindan, Serengulam V, Goldenberg, David M, and Berlin, Jordan D

Abstract

Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or refractory metastatic colorectal cancer. Patients and Methods Eligible patients with at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles. End points were safety, response, pharmacokinetics, and immunogenicity. Results Eighty-six patients who had undergone a median of five prior therapies (range, one to 13) were each enrolled into one of the four cohorts. On the basis of Response Evaluation Criteria in Solid Tumors 1.1, 38% of these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after labetuzumab govitecan treatment; one patient achieved a partial response with a sustained response spanning > 2 years, whereas 42 patients had stable disease as the best overall response. Median progression-free survival and overall survival were 3.6 and 6.9 months, respectively. The major toxicities (grade ≥ 3) among all cohorts were neutropenia (16%), leukopenia (11%), anemia (9%), and diarrhea (7%). The antibody-drug conjugate's mean half-life was 16.5 hours for the four cohorts. Anti-drug/anti-antibody antibodies were not detected. The two once-weekly dose schedules, showing comparable toxicity and efficacy, were chosen for further study. Conclusion Monotherapy with labetuzumab govitecan demonstrated a manageable safety profile and therapeutic activity in heavily pretreated patients with metastatic colorectal cancer, all with prior irinotecan therapy. Further studies of labetuzumab govitecan treatment alone or in combination with other therapies in earlier settings are indicated.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results